89 Results for "

acute leukemia xenograft model

" in MedChemExpress (MCE) Product Catalog:
Products (89)

89 Results for "acute leukemia xenograft model" in MCE Product Catalog:

8
8 Cited Publications
Cat. No.: HY-115364
CAS No.: 14255-87-9
Purity:  99.87%
Synonyms: SKF 29044
Parbendazole (SKF‑29044) is an orally active benzimidazole carbamate compound with multiple biological activities. Parbendazole binds to free tubulin and inhibits microtubule polymerization; it also activates the JNK/c‑Jun signaling axis and upregulates the expression of the downstream axonal repulsion factor Sema3A. Parbendazole upregulates KAL-1 mRNA expression, reduces nerve growth factor levels, and promotes the terminal differentiation of normal human epidermal keratinocytes. Parbendazole induces apoptosis in differentiated acute myeloid leukemia monocytes and exerts antileukemic activity in a mouse xenograft model of acute myeloid leukemia. Parbendazole exhibits broad-spectrum anthelmintic activity against various animal nematodes. Parbendazole is used in research related to acute myeloid leukemia and parasitic infections .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-15815
CAS No.: 1619994-69-2
Purity:  99.89%
Research Areas:  

Cancer

Bromosporine, a chemical probe, is a potent BET inhibitor with an IC50 value of 2.1 μM for PCAF. Bromosporine can arrest cell cycle and induce apoptosis in cancer cells. Bromosporine exhibits excellent antitumor activity in xenograft mice model when combined with 5-Fluorouracil (HY-90006). Bromosporine can increase CDK9 T-loop phosphorylation in HIV-1 latency models, resulting the protection of reactivate HIV-1 replication from latency. Bromosporine can be used to research colorectal cancer, acute myeloid leukemia (AML) and AIDS .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-109565
CAS No.: 1799328-86-1
Purity:  99.81%
Synonyms: ASTX660
Target:  

Apoptosis TNF Receptor IAP

Research Areas:  

Cancer

Tolinapant (ASTX660) is an orally active cIAP1/2 and XIAP antagonist, with an IC50 of < 40 nM against XIAP and an IC50 of <12 nM against cIAP1. Tolinapant triggers TNFα-dependent Apoptosis in cancer cells. Tolinapant inhibits tumor growth in mouse xenograft models. Tolinapant can be used in research related to breast cancer, melanoma, lymphoma, multiple myeloma, acute lymphoblastic leukemia and advanced solid tumors .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-101519
CAS No.: 2093388-62-4
Purity:  99.59%
Synonyms: ZBC 260
BETd-260 (ZBC 260) is a BET PROTAC degrader. BETd-260 recruits BRD2, BRD3, and BRD4 to the CUL4-RBX1-DDB1-CRBN E3 ubiquitin ligase complex, driving cereblon-, proteasome-, and NEDD8-activating enzyme-dependent ubiquitination and degradation, with a DC50 of approximately 30-100 pM in RS4;11 cells. BETd-260 induces cancer cell apoptosis via endogenous signaling pathways, regulates the expression of the Bcl-2 family, inhibits the oncogene c-Myc, and reduces cell viability. BETd-260 suppresses tumor growth in mouse xenograft models with good biosafety. BETd-260 can be used in research related to acute leukemia, hepatocellular carcinoma, osteosarcoma, and triple-negative breast cancer .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-15163
CAS No.: 1204918-72-8
Synonyms: TG02; SB1317
Target:  

JAK CDK FLT3

Research Areas:  

Cancer

Zotiraciclib (TG02; SB1317) is an orally active JAK2/FLT3/CDK2 inhibitor with IC50 values of 13 nM, 73 nM and 56 nM , respectively. Zotiraciclib inhibits cancer cell proliferation, tumor growth and the activity of CYP2D6. Zotiraciclib exhibits high plasma protein binding rate, Caco-2 permeability and tissue distribution capacity, as well as metabolic stability in human and canine liver microsomes. Zotiraciclib achieves tumor growth inhibition in nude mouse models of colon cancer and lymphoma xenografts. Zotiraciclib can be used for research related to colon cancer, B-cell lymphoma, advanced leukemia, acute leukemia and multiple myeloma .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-148813
CAS No.: 2984506-77-4
Purity:  99.73%
Target:  

PROTACs STAT

Research Areas:  

Cancer

AK-2292 is a potent and selective STAT5 PROTAC degrader, with a DC50 of 0.10 μM. AK-2292 induces degradation of STAT5A/B proteins in vitro and in vivo. AK-2292 can induce tumor regression in acute myeloid leukemia and chronic myeloid leukemia xenograft mouse models . AK-2292 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99395
CAS No.: 1826831-79-1
Synonyms: JNJ 56022473; CSL 362

Target:  

Interleukin Related

Research Areas:  

Cancer

Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99272
CAS No.: 1375830-34-4
Synonyms: BMS 936564; MDX 1338; Anti-Human CXCR4 Recombinant Antibody

Target:  

CXCR

Research Areas:  

Cancer

Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-148422
CAS No.: 1139253-73-8
Purity:  99.40%
Research Areas:  

Cancer

Rohinitib is a potent and specific eIF4A inhibitor. Rohinitib induces cell apoptosis of acute myeloid leukemia (AML) cell lines and reduces the leukemia burden of AML xenograft model. Rohinitib can be used for the research of AML .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-172158
CAS No.: 140481-05-6
Research Areas:  

Cancer

ALKBH5-IN-5 is a highly selective ALKBH5 (IC50 = 0.62 μM, Kd = 804 nM). ALKBH5-IN-5 disrupts ALKBH5 binding to m 6A-RNA and 6mA-DNA substrates. ALKBH5-IN-5 promotes differentiation, induces apoptosis, cause G2-M phase arrest and exerts strong antiproliferative effects in cancer cells. ALKBH5-IN-5 reduces TACC3 and MYC protein levels and increases cleaved caspase-3 levels. ALKBH5-IN-5 exerts antitumor activity in tumor xenograft mice models. ALKBH5-IN-5 can be used for the research of acute myeloid leukemia .
loading...
    loading...
Cat. No.: HY-155033
CAS No.: 1875084-68-6
Purity:  99.95%
SSI-4 is an orally active stearoyl-CoA desaturase (SCD1) inhibitor with an EC50 of 1.9 nM against mouse SCD1. SSI-4 blocks the conversion of saturated fatty acids to monounsaturated fatty acids, reducing the production of oleic acid and palmitoleic acid. SSI-4 induces lipid peroxidation, endoplasmic reticulum stress, DNA damage and activates apoptotic mechanisms. SSI-4 inhibits mTORC1 activity, suppresses B cell proliferation and antibody production, and induces autophagy. SSI-4 is applicable to research on cancers such as acute myeloid leukemia and renal cell carcinoma, as well as influenza infections .
loading...
    loading...
Cat. No.: HY-P991558
Synonyms: RG-7356

Research Areas:  

Cancer

RO-5429083 (RG-7356) is a humanized monoclonal antibody targeting CD44. RO-5429083 binds to the extracellular domain of CD44 and inhibits constitutive EGFR phosphorylation. RO-5429083 suppresses tumor growth in xenograft models and can be used in research related to head and neck squamous cell carcinoma and acute myeloid leukemia .
loading...
    loading...
Cat. No.: HY-P99623
CAS No.: 1664355-28-5
Synonyms: MGD006; S80880

Target:  

CD3

Research Areas:  

Cancer

Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and CD3 in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML) .
loading...
    loading...
Cat. No.: HY-171792
Synonyms: ORM-6151
BMS-986497 (ORM-6151) is a CD33-targeting antibody-conjugated GSPT1 degrader. BMS-986497 delivers the GSPT1 degrader SMol006 to CD33-expressing cells and induces GSPT1 protein degradation. BMS-986497 shows potential for research on acute myeloid leukemia (AML) .
loading...
    loading...
Cat. No.: HY-174979
CAS No.: 3084407-00-8
Dac590 is an orally active and selective obesity-associated protein (FTO) inhibitor with an IC50 of 6.06 nM. Dac590 shows highly selective over ALKBH5 and ALKBH3. Dac590 suppresses oncogenic FTO signaling, induces myeloid differentiation, G1-phase cell cycle arrest, and apoptosis in acute myeloid leukemia (AML) cells. Dac590 inhibits xenograft tumor growth and prolongs survival in acute myeloid leukemia mouse models with no observed toxicity. Dac590 can be used for the research of AML .
loading...
    loading...
Cat. No.: HY-P991669
Synonyms: AML-01

Target:  

Caspase Apoptosis

Research Areas:  

Cancer

IGN523 is an anti-CD98 antibody (hCD98, KD = 0.55 nM). IGN523 induces antibody-dependent cell-mediated cytotoxicity (ADCC) activity, lysosomal membrane permeabilization, and inhibition of essential amino acid transport, ultimately leading to caspase-3 and caspase-7-mediated apoptosis of tumor cells. IGN523 inhibits tumor growth in multiple tumor xenograft models. IGN523 is useful in the research of non-small cell lung cancer (NSCLC), acute myeloid leukemia (AML), and other cancers. .
loading...
    loading...
Cat. No.: HY-12854
CAS No.: 868169-64-6
Purity:  99.43%
Synonyms: GRN163L
Target:  

Telomerase Apoptosis

Research Areas:  

Cardiovascular Disease Cancer

Imetelstat (GRN163L) is a 13-mer oligonucleotide and competitive Telomerase inhibitor. Imetelstat binds with high affinity to the template region of the RNA component of human telomerase. Imetelstat induces Apoptosis. Imetelstat is capable of selectively eliminating myelofibrosis hematopoietic stem cells. Imetelstat leads to the loss of a cancer cell's ability to maintain telomere length, resulting in the inhibition of cell proliferation .
loading...
    loading...
Cat. No.: HY-P99916
CAS No.: 2449199-61-3
Synonyms: AMG-427

Target:  

FLT3 CD3 TNF Receptor

Research Areas:  

Inflammation/Immunology Cancer

Emirodatamab (AMG-427) is a bispecific T-cell engager (BiTE). Emirodatamab simultaneously binds FLT3 on the surface of acute myeloid leukemia (AML) cells and CD3 on the surface of T cells, thereby precisely recruiting immune effector cells to tumor sites. Emirodatamab potently induces T cell activation, secretion of proinflammatory cytokines (such as IFNγ, TNFα), and specific cytotoxicity, effectively lysing FLT3-positive tumor cells and inhibiting their growth. Emirodatamab not only significantly prolongs survival in mouse xenograft models and eliminates diseased cells in primates, but also exhibits a synergistic enhancement effect when combined with PD-1 blockade therapy. Emirodatamab is used in studies of acute myeloid leukemia, especially relapsed or refractory cases .
loading...
    loading...
Cat. No.: HY-154984
CAS No.: 3033714-58-5
Purity:  98.07%
Research Areas:  

Cancer

JET-209 is a potent CBP/p300 PROTAC degrader, with DC50 values of 0.05 nM and 0.2 nM for CBP and p300. JET-209 demonstrates remarkable anti-tumor activity against various acute leukemia cell lines and effectively inhibits tumor growth in xenograft tumor models. JET-209 can be used for the study of acute leukemia .
loading...
    loading...
Cat. No.: HY-173320
CAS No.: 3002417-64-0
Research Areas:  

Cancer

HEMTAC WEE1 degrader-1 is a HSP90-mediated targeting chimera (HEMTAC) degrader of WEE1 (HSP90 enzyme inhibitory activity is IC50: 16.76 nM). HEMTAC WEE1 degrader-1 promotes the ubiquitination and degradation of WEE1. HEMTAC WEE1 degrader-1 blocks the G2/M cell cycle. HEMTAC WEE1 degrader-1 has anticancer activity in acute myeloid leukemia (AML) patient-derived xenograft (PDX) models. HEMTAC WEE1 degrader-1 can be used in AML research. (Pink: HSP90 binder; Blue: WEE1 ligand; Black: linker) .
loading...
    loading...